ALNYLAM
Live / Registered — Registered (as of 24 May 2022)
What this means for you
Registered since 24 May 2022. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 87927601
- Registration number
- 6739619
- Mark type
- Stylized text
- Filed
- 18 May 2018
- Published for opposition
- 12 Feb 2019
- Registered
- 24 May 2022
- Attorney of record
- Sarah Anne Keefe
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, namely, RNA therapeutics for use in the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR), hereditary ATTR amyloidosis, hepatic porphyrias, primary hyperoxaluria type 1, Pharmaceuticals, biosimilars and biological preparations for medical and therapeutic purposes for use in the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR), porphyria, hereditary ATTR amyloidosis, hepatic porphyrias, primary hyperoxaluria type 1
Owner
- Alnylam Pharmaceuticals, Inc., Cambridge, MA, US
- Alnylam Pharmaceuticals, Inc., Cambridge, MA, US
- Alnylam Pharmaceuticals, Inc., Cambridge, MA, US
Prosecution history
- 30 Mar 2023 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 30 Mar 2023 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 30 Mar 2023 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 25 May 2022 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 24 May 2022 — REGISTERED-PRINCIPAL REGISTER
- 21 Apr 2022 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 20 Apr 2022 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 19 Apr 2022 — STATEMENT OF USE PROCESSING COMPLETE
- 08 Apr 2022 — USE AMENDMENT FILED
- 08 Apr 2022 — TEAS STATEMENT OF USE RECEIVED
- 16 Sept 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 15 Sept 2021 — SOU EXTENSION 5 GRANTED
- 09 Sept 2021 — SOU EXTENSION 5 FILED
- 15 Sept 2021 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 09 Sept 2021 — SOU TEAS EXTENSION RECEIVED